Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Abuhelaiqa E, Snopkowski C, Li C, Salvatore S, Lee JR, Muthukumar T, et al. Validation of a noninvasive prognostic signature for allograft failure following BK virus associated nephropathy. Clin Transplant. 2021;35(2):e14200.

Bastos DC, Ribeiro CF, Ahearn T, Nascimento J, Pakula H, Clohessy J, et al. Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss. J Pathol. 2021;253(3):292-303.

Shin J-, Choe D, Ransegnola B, Hong H-, Onyekwere I, Cross T, et al. A multifaceted cellular damage repair and prevention pathway promotes high-level tolerance to β-lactam antibiotics. EMBO Rep. 2021;22(2):e51790.

Napoli S, Cascione L, Rinaldi A, Spriano F, Guidetti F, Zhang F, et al. Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma. Haematologica. 2021.

Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zinonos I, et al. ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. Cancer Res. 2021;81(7):1704-1718.

Cheng S, Zhang W, Inghirami G, Tam W. Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking. Elife. 2021;10.

Panza E, Vellecco V, Iannotti FA, Paris D, Manzo OL, Smimmo M, et al. Duchenne's muscular dystrophy involves a defective transsulfuration pathway activity. Redox Biol. 2021;45:102040.

Khan U, Ho K, Hwang EK, Peña C, Brouwer J, Hoffman K, et al. Impact of Use of Antibiotics on Response to Immune Checkpoint Inhibitors and Tumor Microenvironment. Am J Clin Oncol. 2021;44(6):247-253.

Wang X, Gkrouzman E, Andrade DC, Andreoli L, Barbhaiya M, H Belmont M, et al. COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION). Lupus. 2021;30(14):2276-2285.

Deng J, Thennavan A, Dolgalev I, Chen T, Li J, Marzio A, et al. ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer. Nat Cancer. 2021;2(5):503-514.